Assessing the Impact of Scalp Cooling in With Metastatic Breast Cancer
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 4
- 主要终点
- Hair Loss Rate
研究概览
简要总结
This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin.
The name of the study intervention involved in this study is:
- Paxman Scalp Cooling System
详细描述
This study is a prospective, controlled, pivotal clinical investigation to assess the efficacy of the Paxman Scalp Cooling System (PSCS) at preventing hair loss in people undergoing treatment for metastatic breast cancer with either Sacituzumab govitecan (IMMU-132 or Trodelvy™), trastuzumab deruxtecan (DS-8201a or Enhertu®), or Eribulin (Halaven®).
The U.S. Food and Drug Administration (FDA) has approved the Paxman Scalp Cooling System as a treatment option for preventing hair loss while patients are undergoing chemotherapy. This system has however not been specifically studied to look at its ability to prevent hair loss in patients specifically receiving sacituzumab govitecan, trastuzumab deruxtecan, or eribulin.
The research study procedures include: screening for eligibility, photographs, hair loss assessments, questionnaires and study treatment including evaluations and follow up visits.
Participants will receive study treatment with scalp cooling with standard of care chemotherapy treatment and will be followed for 2-4 weeks after completion of treatment with chemotherapy.
It is expected that about 120 people will take part in this research study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women with a diagnosis of metastatic invasive breast cancer with a ECOG PS≤2
- •Participant is ≥ 18 years old.
- •Hair present at baseline.
- •One of the following full dose chemotherapy regimens must be planned for at least 4 cycles:
- •Sacituzumab govitecan (IMMU-132) 10 mg/kg administered intravenously on days 1 and 8 of each 21-day cycle
- •Trastuzumab deruxtecan 5.4 mg/kg administered intravenously once every 3 weeks
- •Eribulin 1.4 mg/m2 administered intravenously on days 1 and 8 of each 21-day cycle
- •The Paxman Scalp Cooling System must be initiated with the first dose of therapy in participants that elect to participate in the scalp cooling group.
排除标准
- •Known hematological malignancies (i.e. leukemia or lymphoma)
- •Known scalp metastases.
- •Baseline alopecia (defined CTCAE 5.0 grade > 0, see Appendix B)
- •Subjects with cold agglutinin disease or cold urticaria.
- •Subjects who are scheduled for bone marrow ablation chemotherapy.
- •Personal history of migraines, cluster or tension headaches as defined as actual medical diagnosis by a physician and/ or prescribed medications. If personal history of migraines was related to a past medical problem that is now resolved, the subject may go on study at the discretion of the Principal Investigator.
- •Subjects who have lichen planus or lupus.
- •Participants who are receiving any additional anti-cancer agents
研究组 & 干预措施
ERIBULIN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)
Participants will use Paxman Scalp Cooling System (PSCS) on days 1, 8 and 21 of each of their standard of care (SOC) treatment cycles with Eribulin.
Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years.
干预措施: Paxman Scalp Cooling System (Device)
ERIBULIN WITHOUT PAXMAN SCALP COOLING SYSTEM (PSCS)
Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with Eribulin.
Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years.
干预措施: Eribulin (Drug)
ERIBULIN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)
Participants will use Paxman Scalp Cooling System (PSCS) on days 1, 8 and 21 of each of their standard of care (SOC) treatment cycles with Eribulin.
Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years.
干预措施: Eribulin (Drug)
SACITUZUMAB GOVITECAN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)
Participants will use Paxman Scalp Cooling System (PSCS) on days 1 and 21 of each of their standard of care (SOC) treatment cycles with SACITUZUMAB GOVITECAN.
Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years.
干预措施: Paxman Scalp Cooling System (Device)
SACITUZUMAB GOVITECAN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)
Participants will use Paxman Scalp Cooling System (PSCS) on days 1 and 21 of each of their standard of care (SOC) treatment cycles with SACITUZUMAB GOVITECAN.
Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years.
干预措施: Sacituzumab govitecan (Drug)
TRASTUZUMAB DERUXTECAN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)
Participants will use Paxman Scalp Cooling System (PSCS) on days 1, 8 and 21 of each of their standard of care (SOC) treatment cycles with TRASTUZUMAB DERUXTECAN.
Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years.
干预措施: Trastuzumab deruxtecan (Drug)
TRASTUZUMAB DERUXTECAN WITH PAXMAN SCALP COOLING SYSTEM (PSCS)
Participants will use Paxman Scalp Cooling System (PSCS) on days 1, 8 and 21 of each of their standard of care (SOC) treatment cycles with TRASTUZUMAB DERUXTECAN.
Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years.
干预措施: Paxman Scalp Cooling System (Device)
SACITUZUMAB GOVITECAN WITHOUT PAXMAN SCALP COOLING SYSTEM (PSCS)
Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with SACITUZUMAB GOVITECAN.
Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years.
干预措施: Sacituzumab govitecan (Drug)
TRASTUZUMAB DERUXTECAN WITHOUT PAXMAN SCALP COOLING SYSTEM
Participants will not use Paxman Scalp Cooling System (PSCS) during their standard of care (SOC) treatment with TRASTUZUMAB DERUXTECAN.
Study cyle is 21 days with total number of cycles based on discretion of treating provider up to 2 years.
干预措施: Trastuzumab deruxtecan (Drug)
结局指标
主要结局
Hair Loss Rate
时间窗: Up to 2 years
Hair loss rate defined as CTCAE v5.0 alopecia grade 1 or higher compared in the scalp cooling group using the Paxman Hair Loss Prevention System (PSCS) and group not using scalp cooling.
次要结局
- Change in Patient Reported Quality of Life(Baseline, Day 1 of cycle 3, day 1 of cycle 5, and after completing therapy or at the time of disease progression whichever occurs first up to 2 years. Cycle is 21 days.)
研究者
Elahe Salehi, NP
Principal Investigator
Dana-Farber Cancer Institute